HLN
$10.60
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Recent News
Eli Lilly (LLY) to Invest $3 Billion in China Over the Next Decade, Reuters Reports
Eli Lilly and Company (NYSE:LLY) is one of the most profitable blue chip stocks to invest in now. Reuters reported on March 11 that Eli Lilly and Company (NYSE:LLY) plans to invest $3 billion in China over the next decade, helping develop production capacity for its experimental type-2 diabetes and obesity treatment orforglipron. In a […]
Jefferies Maintains a Buy on Haleon plc (HLN)
Haleon plc (NYSE:HLN) is one of the Best Young Stocks To Buy and Hold For 20 Year. On March 9, David Hayes from Jefferies maintained a Buy rating on Haleon plc (NYSE:HLN) with a p450.00 price target. The analyst maintained a bullish sentiment despite recent setbacks for the stock, citing that the drag from weaker […]
Advil Maker’s CEO Aims to Play in Weight-Loss Market From Sidelines
Consumer-healthcare group Haleon said supplements to GLP-1 drugs were its best bet in winning a slice of the weight-loss market.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid CPI Inflation Data
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr
Haleon (HLN) Reports 3% Organic Growth in 2025 Driven by ‘Win as One’ Strategy
Haleon (NYSE:HLN) is one of the most promising stocks under $20. On February 25, Haleon reported financial performance for the full-year 2025, marked by the introduction of its ‘Win as One’ strategy and an organic revenue growth of 3%. While results in North America were tempered by low consumer confidence and a weak cold and […]